+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 19Years +
All Genders
ID07670468

Evaluating LB-DTK-MV Cell Therapy for Antiviral-Resistant CMV, BKV, and EBV Infections Following Anticancer Treatment or Stem Cell Transplant

Led by LucasBio · Updated on 2026-06-26

27

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of Multi-Virus Specific T cells LB-DTK-MV in treating patients who have antiviral-resistant infections caused by CMV, BKV, or EBV after receiving anticancer treatments or allogeneic hematopoietic stem cell transplantation allo-HSCT. The study aims to determine the maximum tolerated dose, observe changes in viral loads after treatment, and monitor any adverse events following therapy. Participants will receive two intravenous infusions of LB-DTK-MV. The first infusion is given at the baseline visit at either a low dose 1x107m2 or high dose 2x107m2. A second infusion at the same dose is administered 14 days later. The LB-DTK-MV is a biological cell therapy product derived from a donor and prepared as a cell suspension that is thawed before use. During the study, participants will have weekly follow-up visits at the clinic for six months after the first infusion. Researchers will assess viral loads for CMV, BKV, and EBV, monitor immune responses, and record any treatment-related adverse events throughout the 24 weeks after treatment starts. Various tests including vital signs, physical exams, lab tests, and electrocardiograms will be performed to ensure participant safety and track outcomes.

CONDITIONS

Brief Title

Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.

Research Team

N

Nayoun Kim, Ph.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here